{"totalCount":1,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT07284654","orgStudyIdInfo":{"id":"VAX31-103"},"organization":{"fullName":"Vaxcyte, Inc.","class":"INDUSTRY"},"briefTitle":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49","officialTitle":"A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Immunobridging to Subjects 18-49 Years of Age"},"statusModule":{"statusVerifiedDate":"2025-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-12-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-12-08","studyFirstSubmitQcDate":"2025-12-08","studyFirstPostDateStruct":{"date":"2025-12-16","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-12-08","lastUpdatePostDateStruct":{"date":"2025-12-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vaxcyte, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age."},"conditionsModule":{"conditions":["Pneumococcal Vaccines"],"keywords":["31 Valent PCV","Pneumonia","Pneumococcal Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":4000,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1 (VAX-31), participant ≥ 50 years of age","type":"EXPERIMENTAL","description":"Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1","interventionNames":["Biological: 31 valent pneumococcal conjugate vaccine"]},{"label":"Cohort 1 (PCV21), participant ≥ 50 years of age","type":"ACTIVE_COMPARATOR","description":"Participants will receive a single dose of PCV21 (Capvaxive) administered via intramuscular injection at Day 1","interventionNames":["Biological: PCV21"]},{"label":"Cohort 1 (PCV20), participant ≥ 50 years of age","type":"ACTIVE_COMPARATOR","description":"Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1","interventionNames":["Biological: PCV20"]},{"label":"Cohort 2 (VAX-31), participant 18-49 years of age","type":"EXPERIMENTAL","description":"Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1","interventionNames":["Biological: 31 valent pneumococcal conjugate vaccine"]},{"label":"Cohort 2 (PCV20), participant 18-49 years of age","type":"ACTIVE_COMPARATOR","description":"Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1","interventionNames":["Biological: PCV20"]}],"interventions":[{"type":"BIOLOGICAL","name":"31 valent pneumococcal conjugate vaccine","description":"0.5 mL of VAX-31 will be administered into the deltoid muscle","armGroupLabels":["Cohort 1 (VAX-31), participant ≥ 50 years of age","Cohort 2 (VAX-31), participant 18-49 years of age"]},{"type":"BIOLOGICAL","name":"PCV20","description":"0.5 mL of the 20 valent pneumococcal conjugate vaccine will be administered into the deltoid muscle","armGroupLabels":["Cohort 1 (PCV20), participant ≥ 50 years of age","Cohort 2 (PCV20), participant 18-49 years of age"],"otherNames":["Prevnar 20"]},{"type":"BIOLOGICAL","name":"PCV21","description":"0.5 mL of the 21 valent pneumococcal conjugate vaccine will be administered into the deltoid muscle","armGroupLabels":["Cohort 1 (PCV21), participant ≥ 50 years of age"],"otherNames":["Capvaxive"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Serotype-specific OPA geometric mean titers (GMT) in 50 year olds and above","timeFrame":"1 month after vaccination"},{"measure":"Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site)","timeFrame":"up to 7 days after vaccination"},{"measure":"Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain)","timeFrame":"up to 7 days after vaccination"},{"measure":"Percentage of subjects reporting unsolicited AE","timeFrame":"up to 31 days after vaccination"},{"measure":"Percentage of subjects reporting serious adverse events (SAE), new onset of chronic illness (NOCI), and medically attended adverse events (MAAE)","timeFrame":"up to 6 Months after vaccination"},{"measure":"Serotype-specific OPA geometric mean titers (GMT) in 18 to 49 year olds and 50 to 64 year olds","timeFrame":"1 month after vaccination"}],"secondaryOutcomes":[{"measure":"Serotype-specific IgG geometric mean concentrations (GMC) in 50 year olds and above","timeFrame":"1 month after vaccination"},{"measure":"Serotype-specific IgG GMC in 18 to 49 year olds and 50 to 64 year olds","timeFrame":"1 month after vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥18 years of age (inclusive) at the time of randomization into the study.\n* Able and willing to complete the informed consent process.\n* Available for clinical follow-up through the last study visit.\n* In good general health or with stable underlying chronic condition(s), as determined by medical history, oral temperature, physical examination, and clinical judgment of the Investigator (ongoing chronic conditions must be documented as stable per Investigator).\n* Willing to have blood samples collected and used for research purposes.\n* Able to provide proof of identity to the satisfaction of the site personnel completing the enrollment process.\n* Female participants of childbearing potential, defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test immediately prior to randomization and agree to use acceptable contraception. Male subjects with partners of childbearing potential must agree to practice an acceptable contraception method.\n* Able to access and use a device connected to Wi-Fi or cellular network for completion of an electronic diary (eDiary).\n\nExclusion Criteria:\n\n* History of invasive pneumococcal disease (IPD) or pneumococcal pneumonia (either confirmed or self-reported) at any age.\n* Previous receipt of any licensed or investigational pneumococcal vaccine at any age.\n* Receipt of any investigational product within 30 days prior to Day 1, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study.\n* Receipt of any live vaccine within 30 days prior to Day 1, or receipt of any non-live (including inactivated) vaccine within 14 days prior to Day 1.\n* Body temperature \\>38.0°C (\\>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescreened).\n* Current diagnosis of human immunodeficiency virus, Hepatitis B, or Hepatitis C.\n* History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination.\n* Individual who is pregnant, breastfeeding, or planning to become pregnant during study participation.\n* Has a known or suspected immunocompromising condition, including, but not limited to, leukemia, lymphoma, chronic renal failure, or congenital or acquired immunodeficiency.\n* Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) resulting in clinically significant bruising or bleeding difficulties with IM injections or blood draws.\n* Receipt of blood or blood product (including polyclonal intravenous immunoglobulin) within 60 days prior to enrollment into the study.\n* Is currently receiving immunosuppressive or immune-modifying therapy, including systemic corticosteroids (this includes ≥3 months of prednisone equivalent from 5 to \\<10 mg/day and ≥2 weeks of prednisone equivalent ≥10 mg/day).\n* Received any part of a ≥14-day course of systemic corticosteroids (prednisone equivalent \\>10 mg/day) within 14 days of study vaccination.\n* History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.\n* Any medical, psychiatric, or social condition that in the judgment of the Investigator is a contraindication to protocol participation or impairs a subject's ability to give informed consent.\n* Employee of, or first-degree relative of, any person employed by the Sponsor, the contract research organization (CRO), the Investigator, site personnel, or site.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Clinical Development","role":"CONTACT","phone":"650-837-0111","email":"Clinicaltrialsgov@vaxcyte.com"}],"locations":[{"facility":"Accel Research Site - Achieve - Birmingham - ERN","status":"RECRUITING","city":"Birmingham","state":"Alabama","zip":"35216","country":"United States","contacts":[{"name":"Justina Owens","role":"CONTACT","phone":"205-757-8212","email":"justina.owens@accelclinical.com"},{"name":"Faheem Shaikh","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Center for Indigenous Health - Chinle - Johns Hopkins Project","status":"NOT_YET_RECRUITING","city":"Chinle","state":"Arizona","zip":"86503","country":"United States","contacts":[{"name":"Starla Garcia","role":"CONTACT","phone":"928-674-5051","email":"sgarci34@jhu.edu"},{"name":"Laura Hammitt","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":36.15445,"lon":-109.55261}},{"facility":"Center for Indigineous Health - Whiteriver - John Hopkins Project","status":"NOT_YET_RECRUITING","city":"Whiteriver","state":"Arizona","zip":"85941","country":"United States","contacts":[{"name":"Natalie Jones","role":"CONTACT","phone":"928-338-5215","email":"njones65@jhu.edu"},{"name":"Laura Hammitt","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.83699,"lon":-109.96427}},{"facility":"Clinical Innovations Trials - Riverside - CenExel","status":"RECRUITING","city":"Riverside","state":"California","zip":"92506","country":"United States","contacts":[{"name":"Tina Ramirez","role":"CONTACT","phone":"951-300-4924","email":"t.ramirez@cenexel.com"},{"name":"Grace K Morehart, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.95335,"lon":-117.39616}},{"facility":"Research Centers of America - Hollywood - CenExel","status":"RECRUITING","city":"Hollywood","state":"Florida","zip":"33024","country":"United States","contacts":[{"name":"Laymis Alvarez","role":"CONTACT","phone":"954-990-7649","email":"L.alvarez@cenexel.com"},{"name":"Craig Shapiro","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Health Awareness - Jupiter - ERN","status":"RECRUITING","city":"Jupiter","state":"Florida","zip":"33458","country":"United States","contacts":[{"name":"Sara Hernandez","role":"CONTACT","phone":"561-741-2033","email":"sara@healthawareness.com"},{"name":"Ronald Z Surowitz, DO","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":26.93422,"lon":-80.09421}},{"facility":"Suncoast Research Group LLC","status":"RECRUITING","city":"Miami","state":"Florida","zip":"33135","country":"United States","contacts":[{"name":"Joeb I Gonzalez","role":"CONTACT","phone":"305-631-6704","email":"jigonzalez@flourishresearch.com"},{"name":"Mark E Kutner","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Precision Clinical Research - Sunrise","status":"RECRUITING","city":"Sunrise","state":"Florida","zip":"33351","country":"United States","contacts":[{"name":"Emily Bird","role":"CONTACT","phone":"954-915-9991","email":"emilyb@pcrflorida.com"},{"name":"Jason M. Haffizulla, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":26.13397,"lon":-80.1131}},{"facility":"Clinical Research Atlanta - Headlands","status":"RECRUITING","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","contacts":[{"name":"Michelle Binns","role":"CONTACT","phone":"770-507-6867","email":"michelle.binns@clinicalresearchatlanta.com"},{"name":"Jon Finley, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"Velocity Clinical Research - Valparaiso (Buynak Clinical Research)","status":"RECRUITING","city":"Valparaiso","state":"Indiana","zip":"46383","country":"United States","contacts":[{"name":"Miranda Lee","role":"CONTACT","phone":"219-464-8302","email":"mlee@velocityclinical.com"},{"name":"Robert Buynak","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.47309,"lon":-87.06114}},{"facility":"Johnson County Clin-Trials - JCCT","status":"RECRUITING","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","contacts":[{"name":"Melissa Pittman","role":"CONTACT","phone":"913-825-4400","email":"mpittman@jcct.com"},{"name":"Carlos Fierro, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Alliance for Multispecialty Research, LLC - West Wichita","status":"RECRUITING","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","contacts":[{"name":"Seneca Meeks","role":"CONTACT","phone":"316-689-6635","email":"seneca.meeks@amr-clinical.com"},{"name":"Terry D Klein, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"DelRicht Clinical Research, LLC - New Orleans","status":"RECRUITING","city":"New Orleans","state":"Louisiana","zip":"70115","country":"United States","contacts":[{"name":"Morgan Couvillion","role":"CONTACT","phone":"504-336-2667","email":"mcouvillion@delricht.com"},{"name":"Patrick Dennis","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.95465,"lon":-90.07507}},{"facility":"Headlands Research - Detroit - Headlands","status":"RECRUITING","city":"Southfield","state":"Michigan","zip":"48034","country":"United States","contacts":[{"name":"Tianna Walker","role":"CONTACT","phone":"248-243-1870","email":"tianna.walker@headlandsresearch.com"},{"name":"David Strong, MD, PhD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.47337,"lon":-83.22187}},{"facility":"DelRicht Research, LLC - Gulfport","status":"RECRUITING","city":"Gulfport","state":"Mississippi","zip":"39503","country":"United States","contacts":[{"name":"Amber Laque","role":"CONTACT","phone":"228-588-8268","email":"alaque@delricht.com"},{"name":"Sean Kerby","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":30.36742,"lon":-89.09282}},{"facility":"Sky Integrative Medical Center - SKYCRNG","status":"RECRUITING","city":"Ridgeland","state":"Mississippi","zip":"39157","country":"United States","contacts":[{"name":"Monica Wiley","role":"CONTACT","phone":"601-617-7717","email":"monica.wiley@skycrng.com"},{"name":"Bob Hutchins, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.42848,"lon":-90.13231}},{"facility":"Alliance for Multispecialty Research, LLC - Kansas City","status":"RECRUITING","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","contacts":[{"name":"Kara M Farren","role":"CONTACT","phone":"816-943-0770","email":"kara.farren@amr-clinical.com"},{"name":"Martha Sue Fanning","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Velocity Clinical Research","status":"RECRUITING","city":"Omaha","state":"Nebraska","zip":"68134","country":"United States","contacts":[{"name":"Cortney Roach","role":"CONTACT","phone":"402-933-6500","email":"croach@velocityclinical.com"},{"name":"Frederick C Raiser, III","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Advanced Memory Research Institute - CenExe","status":"RECRUITING","city":"Toms River","state":"New Jersey","zip":"08755","country":"United States","contacts":[{"name":"Laure Bawiec","role":"CONTACT","phone":"732-341-9500","email":"l.bawiec@cenexel.com"},{"name":"Arun Singh","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.95373,"lon":-74.19792}},{"facility":"Center for Indigineous Health - Gallup - John Hopkins Project","status":"NOT_YET_RECRUITING","city":"Gallup","state":"New Mexico","zip":"87301","country":"United States","contacts":[{"name":"Carol Tso","role":"CONTACT","phone":"505-722-6865","email":"ctso1@jhu.edu"},{"name":"Laura Hammitt","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":35.52808,"lon":-108.74258}},{"facility":"Center for Indigineous Health - Shiprock - John Hopkins Project","status":"NOT_YET_RECRUITING","city":"Shiprock","state":"New Mexico","zip":"87420","country":"United States","contacts":[{"name":"Mary Thomas","role":"CONTACT","phone":"505-368-4030","email":"mthom188@jhu.edu"},{"name":"Laura Hammitt","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":36.78555,"lon":-108.68703}},{"facility":"Rochester Clinical Research - ATLAS - Rochester","status":"RECRUITING","city":"Rochester","state":"New York","zip":"14609","country":"United States","contacts":[{"name":"Megan Boise","role":"CONTACT","phone":"585-288-0890","email":"mboise@rcrclinical.com"},{"name":"Matthew Davis, M.D.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":43.15478,"lon":-77.61556}},{"facility":"CTI Clinical Research Center","status":"RECRUITING","city":"Cincinnati","state":"Ohio","zip":"45212","country":"United States","contacts":[{"name":"Angie Winkler","role":"CONTACT","phone":"513-281-1362","email":"awinkler@ctifacts.com"},{"name":"Antoinette Pragalos","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Lynn Institute of Norman","status":"RECRUITING","city":"Norman","state":"Oklahoma","zip":"73072","country":"United States","contacts":[{"name":"Samantha Ting","role":"CONTACT","phone":"405-701-2540","email":"Sting@lhsi.net"},{"name":"Steven Cox, D.O","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":35.22257,"lon":-97.43948}},{"facility":"DM Clinical Research - Philadelphia","status":"RECRUITING","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","contacts":[{"name":"Ciani Perez","role":"CONTACT","phone":"267-376-9392","email":"ciani.perez@dmclinical.com"},{"name":"David S Wheeler, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Coastal Carolina Research Center - Alcanza - HyperCore","status":"RECRUITING","city":"North Charleston","state":"South Carolina","zip":"29405","country":"United States","contacts":[{"name":"Anna Wright","role":"CONTACT","phone":"843-856-3784","email":"anna.wright@coastalcarolinaresearch.com"},{"name":"Kelly Nicole Morales, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.85462,"lon":-79.97481}},{"facility":"Flourish Research - San Antonio","status":"RECRUITING","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","contacts":[{"name":"LaToya Gates","role":"CONTACT","phone":"210-949-0122","email":"lgates@flourishresearch.com"},{"name":"Parke Hedges","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"DM Clinical Research - Sugarland","status":"RECRUITING","city":"Sugar Land","state":"Texas","zip":"77478","country":"United States","contacts":[{"name":"Laila Sikanderali","role":"CONTACT","phone":"346-550-9559","email":"laila.sikanderali@dmclinical.com"},{"name":"Lisa R Holloway, DO","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":29.61968,"lon":-95.63495}},{"facility":"JBR Clinical Research - CenExel JBR","status":"RECRUITING","city":"Salt Lake City","state":"Utah","zip":"84107","country":"United States","contacts":[{"name":"Sage-Marie Fogg","role":"CONTACT","phone":"801-261-2000","email":"s.fogg@cenexel.com"},{"name":"Todd Bertoch, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Charlottesville Medical Research Center - Alcanza - HyperCore","status":"RECRUITING","city":"Charlottesville","state":"Virginia","zip":"22911","country":"United States","contacts":[{"name":"Mary E Claros","role":"CONTACT","phone":"434-817-2442","email":"Mary.Esplin@cvillemedresearch.com"},{"name":"James Clark, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":38.02931,"lon":-78.47668}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Vaxcyte is committed to providing access to anonymized data from the company's clinical trials for the purpose of legitimate scientific research. Requests for data may be addressed to datasharing@vaxcyte.com. Requests must be accompanied by a detailed analysis plan and will be reviewed for scientific validity. Data will be made available after initial product approval. Sharing of data may require execution of a data-sharing agreement.","infoTypes":["STUDY_PROTOCOL"],"timeFrame":"Individual participant data will be shared after deidentification and made available starting 6 months after initial product approval.","accessCriteria":"Criteria will depend on the specific proposal received and may include qualification of the scientific researchers, potential contribution to the research field, scientific rigor of statistical and analytical methods, and other criteria appropriate for the proposal."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D011014","term":"Pneumonia"},{"id":"D011008","term":"Pneumococcal Infections"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D013290","term":"Streptococcal Infections"},{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"}]}},"hasResults":false}
]}